

# PRotection by Offering Human papillomavirus Testing on sELf-sampled Cervicovaginal specimens Trial

<b>Submission date</b> 28/12/2006	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 28/12/2006	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 06/01/2021	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

**Study website**  
<http://www.hpvthuistest.nl>

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr D A M Heideman

**Contact details**  
VU University Medical Center  
Department of Pathology  
PO Box 7057  
Amsterdam  
Netherlands  
1007 MB  
-  
[dam.heideman@vumc.nl](mailto:dam.heideman@vumc.nl)

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**

**Secondary identifying numbers**

2006/01WBO

## **Study information**

### **Scientific Title**

PRotection by Offering Human papillomavirus Testing on sELf-sampled Cervicovaginal specimens Trial

### **Acronym**

PROHTECT

### **Study objectives**

The main aims of the PROHTECT trial are to find out whether the compliance rate of the cervical screening programme can be improved by offering a self-sampling method for collecting cervicovaginal cell material at home for Human PapillomaVirus (HPV) testing, and consequently the (cost)-effectiveness of screening will be enhanced due to increased detection of high grade Cervical Intraepithelial Neoplasia (CIN) lesions or worse (more than or equal to CIN grade two to three)?

### **Ethics approval required**

Old ethics approval format

### **Ethics approval(s)**

The PROHTECT trial has been approved by the Dutch Ministry of Health, Welfare and Sports (reference number: 2006/01WBO), date of approval: 11/05/2006. In addition, the Ethics Board of the VU University Medical Center has approved the study.

### **Study design**

Randomised controlled parallel-group trial

### **Primary study design**

Interventional

### **Secondary study design**

Randomised controlled trial

### **Study setting(s)**

Not specified

### **Study type(s)**

Screening

### **Participant information sheet**

### **Health condition(s) or problem(s) studied**

Cervical Intraepithelial Neoplasia (CIN), cervix cancer, uterus

## **Interventions**

In the PROHTECT trial, the effect of the addition of offering self-sampling at home to women who are not responding to the invitation of the regular cervical screening program as well as a first recall, onto the participation rate is evaluated in a randomised controlled trial design.

During the trial, participants will receive either a second recall for the regular screening (control group), or receive a kit for self-sampling of a cervicovaginal specimen at home and subsequent referral recommendations based on the presence or absence of high-risk Human PapillomaVirus (hrHPV) in the self-taken specimen (intervention group, hrHPV test results disclosed).

## **Intervention Type**

Other

## **Phase**

Not Specified

## **Primary outcome measure**

The primary outcome measure is the change in compliance rate, i.e., the increase in attendance rate of the cervical screening program after a second recall by using self-sampling material for hrHPV testing, compared to a control group that will receive a second recall for cytological testing (similar to the conventional first recall).

## **Secondary outcome measures**

The secondary outcome measures include:

1. The women characteristics, i.e., the prevalence of HPV and the number of detected high-grade CIN lesions for compliance of referral and treatment among non-responder women compared to women participating in the conventional screening program.
2. Evaluation of the cost-effectiveness of self-sampling when offered in the nation-wide screening program, i.e., counter valuation of the effects on costs versus improved detection rate of premalignant lesions.

## **Overall study start date**

01/10/2006

## **Completion date**

01/03/2009

# **Eligibility**

## **Key inclusion criteria**

1. Women invited for the cervical cancer screening program (ages 30 to 60 years), but who are not responding to their invitation as well as their recall (three months after)
2. Residing in the region covered by district health authorities of North Holland and Flevoland (in the Netherlands)

## **Participant type(s)**

Patient

## **Age group**

Adult

**Sex**

Female

**Target number of participants**

45000

**Total final enrolment**

28073

**Key exclusion criteria**

1. Not called for screening, i.e., ages under 30 years, or over 60 years
2. Actively responded to the invitation or first recall of the cervical screening program by undergoing a cervical smear at the general practitioner
3. Living outside the region covered by district health authorities of North Holland and Flevoland
4. Under follow-up by gynaecologist for previous non-normal cytology, i.e., abnormal cytology and/or CIN three lesion or worse less than two years before inclusion
5. Current pregnancy
6. Status after extirpation of the uterus or amputation of the portio

**Date of first enrolment**

01/10/2006

**Date of final enrolment**

01/03/2009

**Locations****Countries of recruitment**

Netherlands

**Study participating centre**

VU University Medical Center

Amsterdam

Netherlands

1007 MB

**Sponsor information****Organisation**

VU University Medical Center

**Sponsor details**

Department of Pathology

PO Box 7057

Amsterdam

Netherlands  
1007 MB  
-  
cjl.m.meijer@vumc.nl

**Sponsor type**  
Hospital/treatment centre

**Website**  
<http://www.vumc.nl/>

**ROR**  
<https://ror.org/00q6h8f30>

## Funder(s)

**Funder type**  
Hospital/treatment centre

**Funder Name**  
Comprehensive Cancer Centre (Integraal Kankercentrum) (The Netherlands) 2. VU University Medical Center (The Netherlands) 3. National Institute of Public Health and Environmental Protection (RIVM) (The Netherlands)

## Results and Publications

**Publication and dissemination plan**  
Not provided at time of registration

**Intention to publish date**

**Individual participant data (IPD) sharing plan**

**IPD sharing plan summary**  
Not provided at time of registration

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	11/03/2010	06/01/2021	Yes	No